Assurance de qualité pour le cancer rectal – phase 2 ...

KCE Reports 81 PROCARE – phase 2 27AllMalesFemalesTable 14. 5-year relative survival rate by (y)pStage using the administrativedatabases*, calculated with actuarial (life table) method.(y)p-stage N N deaths on31/12/20061-year 2-year 3-year 4-year 5-yearI 892 226 96% 96% 93% 91% 89%II 1192 460 93% 89% 82% 76% 71%III 1094 610 88% 75% 63% 55% 50%IV 352 292 72% 48% 30% 19% 17%X 3544 1911 78% 68% 61% 57% 53%I-III 3178 1296 92% 86% 79% 73% 69%Total (I-IV) 7074 3499 84% 75% 68% 62% 58%I 547 147 95% 95% 92% 91% 88%II 704 259 94% 90% 85% 79% 75%III 629 369 87% 73% 60% 52% 47%IV 227 193 71% 49% 29% 16% 13%X 2025 1099 79% 69% 62% 57% 54%I-III 1880 775 92% 86% 79% 73% 69%Total (I-IV) 4132 2067 85% 76% 68% 62% 59%I 345 79 98% 97% 94% 91% 90%II 488 201 91% 86% 78% 72% 66%III 465 241 89% 76% 67% 58% 53%IV 125 99 74% 47% 30% 24% 22%X 1519 812 75% 67% 61% 57% 53%I-III 1298 521 92% 85% 78% 72% 68%Total (I-IV) 2942 1432 83% 74% 67% 62% 58%* Mean follow-up: 38 months (range 0-83 months).Figure 6 provides an overview of the 5-year relative survival of the (y)pStage I-IIIpatients per centre using the administrative database. The 5-year relative survival rangesfrom 12 – 130%. Fifty-seven and 55 centres have a 5-year relative survival above theweighted (69%; 95%CI 67 – 70%) and unweighted mean (69%; 95%CI 65 – 73%)respectively.Figure 6. Per-centre-analysis (n = 112) of the 5-year relative survival of(y)pStage I-III patients (administrative cohort) $ .1002009018080160Proportion (%)70605040301401201008060Number of patients (N)2040102000$ The weighted mean is presented with a red bar, the unweighted mean is presented with a bluehorizontal line. The grey bars represent the QI value per centre, while the blue dots representthe number of patients per centre. These results are preliminary, and cannot be used to judge thequality of care.